Head and Neck Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major head and neck cancer markets reached a value of US$ 3,252.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7,279.8 Million by 2034, exhibiting a growth rate (CAGR) of 7.6% during 2024-2034.
The head and neck cancer market has been comprehensively analyzed in IMARC’s new report titled “Head and Neck Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Head and neck cancer refers to the term used to describe a variety of malignant tumors that develop in or around the throat, larynx, sinuses, nose, and mouth. Such forms of cancer are hard to diagnose, and the symptoms are very mild. These cancers can mimic less severe conditions such as cold and sore throat, and the symptoms may include a mouth or tongue sore that does not heal on its own, a white or a red patch on the gums, tongue, or the lining area of the mouth, a persistent sore throat, and hoarseness. Head and neck cancer can be hard to diagnose and early detection is necessary to successfully treat both cancers. Some of the techniques that are advised for diagnosing head and neck malignancies include a physical exam that may be used to check on the oral and nasal cavities, an endoscopic examination, and laboratory testing using blood, urine, and other body samples. Other tests include head and neck X-rays, CAT scans, MRIs, and PET scans to view images inside the neck and head. The two primary treatment modalities are surgery and radiotherapy. Clinical results have improved due to better surgical and radiation treatment approaches and the use of systemic medicines in curative therapy.
The increasing prevalence of head and neck cancer on account of the rising consumption of alcoholic beverages and tobacco-based products is primarily driving the head and neck cancer market. In line with this, the growing incidences of infectious diseases (human papillomavirus/Epstein bar virus), nutritional deficiencies, and underlying genetic disorders are further augmenting the market growth. Moreover, the emerging popularity of cancer immunotherapy owing to the growing awareness regarding its efficacy and fewer side effects as compared to traditional chemotherapy is also creating a positive outlook for the market. Additionally, the introduction of advanced oncological imaging modalities and imaging technologies to detect infections with enhanced accuracy is further bolstering the global market. Besides this, several key players are making significant investments to produce cancer vaccines and novel biomarkers for the identification of potential tumors. This, in turn, is also acting as another growth-inducing factor. Moreover, the launch of favorable initiatives by various non-governmental organizations (NGOs) and healthcare practitioners to sensitize individuals about the benefits of early cancer diagnosis, including instant decision-making and consequent treatment, is further fueling the market growth. Numerous other factors, such as the increasing regulatory approvals for new cancer immunotherapy drugs, technological advancements in clinical therapies, and the emerging popularity of targeted molecular therapy, including gene therapy, monoclonal antibodies, antibody drug conjugates, etc., are expected to drive the global head and neck cancer market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the head and neck cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for head and neck cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the head and neck cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the head and neck cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the head and neck cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current head and neck cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the head and neck cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the head and neck cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the head and neck cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the head and neck cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of head and neck cancer?
What will be the growth rate of patients across the seven major markets?
Head and Neck Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for head and neck cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the head and neck cancer market?
The head and neck cancer market has been comprehensively analyzed in IMARC’s new report titled “Head and Neck Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Head and neck cancer refers to the term used to describe a variety of malignant tumors that develop in or around the throat, larynx, sinuses, nose, and mouth. Such forms of cancer are hard to diagnose, and the symptoms are very mild. These cancers can mimic less severe conditions such as cold and sore throat, and the symptoms may include a mouth or tongue sore that does not heal on its own, a white or a red patch on the gums, tongue, or the lining area of the mouth, a persistent sore throat, and hoarseness. Head and neck cancer can be hard to diagnose and early detection is necessary to successfully treat both cancers. Some of the techniques that are advised for diagnosing head and neck malignancies include a physical exam that may be used to check on the oral and nasal cavities, an endoscopic examination, and laboratory testing using blood, urine, and other body samples. Other tests include head and neck X-rays, CAT scans, MRIs, and PET scans to view images inside the neck and head. The two primary treatment modalities are surgery and radiotherapy. Clinical results have improved due to better surgical and radiation treatment approaches and the use of systemic medicines in curative therapy.
The increasing prevalence of head and neck cancer on account of the rising consumption of alcoholic beverages and tobacco-based products is primarily driving the head and neck cancer market. In line with this, the growing incidences of infectious diseases (human papillomavirus/Epstein bar virus), nutritional deficiencies, and underlying genetic disorders are further augmenting the market growth. Moreover, the emerging popularity of cancer immunotherapy owing to the growing awareness regarding its efficacy and fewer side effects as compared to traditional chemotherapy is also creating a positive outlook for the market. Additionally, the introduction of advanced oncological imaging modalities and imaging technologies to detect infections with enhanced accuracy is further bolstering the global market. Besides this, several key players are making significant investments to produce cancer vaccines and novel biomarkers for the identification of potential tumors. This, in turn, is also acting as another growth-inducing factor. Moreover, the launch of favorable initiatives by various non-governmental organizations (NGOs) and healthcare practitioners to sensitize individuals about the benefits of early cancer diagnosis, including instant decision-making and consequent treatment, is further fueling the market growth. Numerous other factors, such as the increasing regulatory approvals for new cancer immunotherapy drugs, technological advancements in clinical therapies, and the emerging popularity of targeted molecular therapy, including gene therapy, monoclonal antibodies, antibody drug conjugates, etc., are expected to drive the global head and neck cancer market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the head and neck cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for head and neck cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the head and neck cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the head and neck cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the head and neck cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current head and neck cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the head and neck cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the head and neck cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the head and neck cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the head and neck cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of head and neck cancer?
What will be the growth rate of patients across the seven major markets?
Head and Neck Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for head and neck cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the head and neck cancer market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEAD AND NECK CANCER - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (2024-2034?)
4.4 Competitive Intelligence
5 HEAD AND NECK CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEAD AND NECK CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
8 HEAD AND NECK CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEAD AND NECK CANCER - UNMET NEEDS
10 HEAD AND NECK CANCER - KEY ENDPOINTS OF TREATMENT
11 HEAD AND NECK CANCER - MARKETED PRODUCTS
11.1 List of Head and Neck Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Erbitux (Cetuximab) – Eli Lilly and Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Docetaxel (Taxotere) – CSPC ZhongQi Pharmaceutical Technology
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Hydrea (Hydroxyurea) - Bristol-Myers Squibb
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Temodar (Temozolomide) - Merck & Co
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Avastin (Bevacizumab) - Genentech
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 HEAD AND NECK CANCER - PIPELINE DRUGS
12.1 List of Head and Neck Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Avelumab - Merck KGaA
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Avasopasem - Galera Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Tigilanol tiglate - QBiotics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Hafnium oxide - Nanobiotix
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Erlotinib - Astellas Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. HEAD AND NECK CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 HEAD AND NECK CANCER - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Head and Neck Cancer - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034?)
14.2.2 Head and Neck Cancer - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034?)
14.3 Market Scenario - United States
14.3.1 Head and Neck Cancer - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034?)
14.3.2 Head and Neck Cancer - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034?)
14.3.3 Head and Neck Cancer - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Head and Neck Cancer - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034?)
14.4.2 Head and Neck Cancer - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034?)
14.4.3 Head and Neck Cancer - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Head and Neck Cancer - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034?)
14.5.2 Head and Neck Cancer - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034?)
14.5.3 Head and Neck Cancer - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Head and Neck Cancer - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034?)
14.6.2 Head and Neck Cancer - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034?)
14.6.3 Head and Neck Cancer - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Head and Neck Cancer - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034?)
14.7.2 Head and Neck Cancer - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034?)
14.7.3 Head and Neck Cancer - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Head and Neck Cancer - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034?)
14.8.2 Head and Neck Cancer - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034?)
14.8.3 Head and Neck Cancer - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Head and Neck Cancer - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034?)
14.9.2 Head and Neck Cancer - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034?)
14.9.3 Head and Neck Cancer - Access and Reimbursement Overview
15 HEAD AND NECK CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 HEAD AND NECK CANCER MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEAD AND NECK CANCER - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (2024-2034?)
4.4 Competitive Intelligence
5 HEAD AND NECK CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEAD AND NECK CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
8 HEAD AND NECK CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEAD AND NECK CANCER - UNMET NEEDS
10 HEAD AND NECK CANCER - KEY ENDPOINTS OF TREATMENT
11 HEAD AND NECK CANCER - MARKETED PRODUCTS
11.1 List of Head and Neck Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Erbitux (Cetuximab) – Eli Lilly and Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Docetaxel (Taxotere) – CSPC ZhongQi Pharmaceutical Technology
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Hydrea (Hydroxyurea) - Bristol-Myers Squibb
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Temodar (Temozolomide) - Merck & Co
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Avastin (Bevacizumab) - Genentech
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 HEAD AND NECK CANCER - PIPELINE DRUGS
12.1 List of Head and Neck Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Avelumab - Merck KGaA
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Avasopasem - Galera Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Tigilanol tiglate - QBiotics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Hafnium oxide - Nanobiotix
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Erlotinib - Astellas Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. HEAD AND NECK CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 HEAD AND NECK CANCER - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Head and Neck Cancer - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034?)
14.2.2 Head and Neck Cancer - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034?)
14.3 Market Scenario - United States
14.3.1 Head and Neck Cancer - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034?)
14.3.2 Head and Neck Cancer - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034?)
14.3.3 Head and Neck Cancer - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Head and Neck Cancer - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034?)
14.4.2 Head and Neck Cancer - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034?)
14.4.3 Head and Neck Cancer - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Head and Neck Cancer - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034?)
14.5.2 Head and Neck Cancer - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034?)
14.5.3 Head and Neck Cancer - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Head and Neck Cancer - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034?)
14.6.2 Head and Neck Cancer - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034?)
14.6.3 Head and Neck Cancer - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Head and Neck Cancer - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034?)
14.7.2 Head and Neck Cancer - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034?)
14.7.3 Head and Neck Cancer - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Head and Neck Cancer - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034?)
14.8.2 Head and Neck Cancer - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034?)
14.8.3 Head and Neck Cancer - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Head and Neck Cancer - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034?)
14.9.2 Head and Neck Cancer - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034?)
14.9.3 Head and Neck Cancer - Access and Reimbursement Overview
15 HEAD AND NECK CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 HEAD AND NECK CANCER MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
